Rational engineering of a native hyperthermostable lactonase into a broad spectrum phosphotriesterase

Pauline Jacquet1, Julien Hiblot1,4, David Daudé2, Céline Bergonzi1,3, Guillaume Gotthard1, Nicholas Armstrong1, Eric Chabrière1 & Mikael Elias3

The redesign of enzyme active sites to alter their function or specificity is a difficult yet appealing challenge. Here we used a structure-based design approach to engineer the lactonase SsoPox from Sulfolobus solfataricus into a phosphotriesterase. The five best variants were characterized and their structure was solved. The most active variant, αsD6 (V27A-Y97W-L228M-W263M) demonstrates a large increase in catalytic efficiencies over the wild-type enzyme, with increases of 2,210-fold, 163-fold, 58-fold, 16-fold against methyl-parathion, malathion, ethyl-paraoxon, and methyl-paraoxon, respectively. Interestingly, the best mutants are also capable of degrading fensulfothion, which is reported to be an inhibitor for the wild-type enzyme, as well as others that are not substrates of the starting template or previously reported W263 mutants. The broad specificity of these engineered variants makes them promising candidates for the bioremediation of organophosphorus compounds. Analysis of their structures reveals that the increase in activity mainly occurs through the destabilization of the active site loop involved in substrate binding, and it has been observed that the level of disorder correlates with the width of the enzyme specificity spectrum. This finding supports the idea that active site conformational flexibility is essential to the acquisition of broader substrate specificity.

Enzymes are extraordinary molecules that can accelerate chemical reactions, including those that spontaneously occur extremely slowly, and can make them happen many times per second1. Some of these reactions are of high biotechnological or industrial interest and enzymes are, therefore, the focus of numerous studies2. However, enzymes are often not directly compatible with industrial processes for various reasons ranging from their sub-optimality3,4 or lack of stability under certain conditions5. The properties of enzymes can be tuned by molecular engineering to fit these new requirements using high throughput methods such as directed evolution5–10 and/or low throughput methods, reducing the size of the library by focusing on positions that can be saturated11–13, or by using phylogenetically-inferred14,15 or structure-based mutations to create combinatorial16, reduced libraries17.

Here, we focus on the molecular engineering of an enzymatic bio-decontaminant of organophosphates compounds (OPs), including nerve agents and insecticides. These compounds are neurotoxic because of their ability to irreversibly inhibit the acetylcholine esterase, a key enzyme in the nervous system18. Massively used in agriculture as pesticides19, they were modified before World War II to increase their toxicity and develop chemical warfare agents20. OPs still represent major environmental, health and security concerns, as they cause significant pollution21,22, and intoxication, and have been used in terrorist attacks19,20. However, since current methods for removing them are cost prohibitive and lead to ecological concerns, enzymatic remediation is a promising way of developing efficient bio-decontamination methods23–25.

Phosphotriesterase-like Lactonases (PLLs) are appealing candidates, being natural lactonases endowed with promiscuous phosphotriesterase activity26. They have long been related to the bacterial phosphotriesterases (PTEs), enzymes which are capable of hydrolyzing insecticides such as parathion with high catalytic efficiency27. PTEs and PLLs belong to the amidohydrolase superfamily28,29, and share the same (β/α)8 barrel topology. Some

1CNRS UMR 7278, IRD198, INSERM U1095, APHM, Institut Hospitalier Universitaire Méditerranée-Infection, Aix-Marseille Université, 19-21 Bd Jean Moulin, 13005, Marseille, France. 2Gene&GreenTK, IHU Méditerranée Infection, 19-21 Bd Jean Moulin, 13005, Marseille, France. 3University of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics & Biotechnology Institute, St. Paul, MN, 55108, USA. 4Present address: MPI for Medical Research, Chemical Biology department (EPFL), Heidelberg, Germany. Pauline Jacquet, Julien Hiblot and David Daudé contributed equally to this work. Correspondence and requests for materials should be addressed to E.C. (email: eric.chabriere@univ-amu.fr) or M.E. (email: mhelias@umn.edu)
Pox is a very appealing candidate for the bioremediation of phosphotriesters because of its unique thermal stability, and its ability to resist aging, solvent and protease treatments. On the other hand, SsoPox is a poor phosphotriesterase. Previous work showed that engineering can successfully improve PTEs and PLLs' active sites mainly differ in their loop length (7 and 8), sequences and conformations, loop grafting experiments were performed and produced a structure-based combinatorial library, and screened this library for improved phosphotriesterase activity with the aim of obtaining heat stable, highly active variants with broad specificity. We obtained several improved variants reveal that the selected mutations increase the active site loop conformational flexibility and reshape the active site. The best variants were extensively characterized against eight commercially available phosphotriester substrates.

### Table 1. Data collection and refinement statistics of SsoPox variants structures.

| Data collections | asA6 open | asA6 closed | asB5 | asC6 | asD6 | asA1 |
|------------------|-----------|-------------|------|------|------|------|
| PDB ID           | 5VRK      | 5VRI        | 5W3U | 5W3Z | 5W3W | 5VSA |
| Wavelength (Å)   | 0.97934   | 0.93340     | 0.97625 | 1.00882 | 1.00882 | 0.99987 |
| Resolution (Å)   | 1.4       | 2.1          | 2.5   | 2.55  | 2.95  | 2.0  |
| Space group      | P2₁       | P2₁,2₁      | P2₁,2₁,2₁  | P2₁,2₁ | P2₁,2₁ | P2₁,2₁ |

### Unit cell dimensions

|   | a (Å)   | b (Å)   | c (Å)   | α (°) | β (°) | γ (°) |
|---|---------|---------|---------|-------|-------|-------|
| a | 49.28   | 137.20  | 49.36   | 90.0  | 98.7  | 90.0  |
| b | 87.17   | 103.61  | 152.61  |       |       |       |
| c | 82.93   | 105.95  | 152.83  |       |       |       |
| α| 81.65   | 105.80  | 154.53  |       |       |       |
| β| 82.34   | 105.01  | 153.15  |       |       |       |
| γ| 86.6    | 103.10  | 151.8   |       |       |       |

### Refinement statistics

| Resolution range (Å) | 48.7128–1.40 | 49.0556–2.1500 | 49.6449–2.500 | 46.313–2.55 | 49.667–2.95 | 48.812–2.0 |
|----------------------|---------------|----------------|---------------|------------|------------|------------|
| No. reflections      | 115818        | 70416          | 44736         | 41042      | 26754      | 86547      |
| Rfree / Rwork        | 21.35/17.23   | 27.17/21.22    | 24.15/19.97   | 28.31/24.68 | 20.55/16.32 | 20.55/16.32 |
| No. protein atoms    | 5368          | 10122          | 9310          | 9657       | 9683       | 9987       |
| No. water molecules  | 634           | 659            | 76            | 154        | 23         | 733        |
| Average B factor (Å²)| 19.095        | 24.984         | 86.6          | 80.375     | 95.992     | 29.885     |

### rmsd from ideal

| Bond lengths (Å) | 0.0088 | 0.0028 | 0.0050 | 0.0110 | 0.0070 | 0.0211 |
| Bond angles (°)  | 1.0703 | 0.7309 | 0.8490 | 1.1730 | 0.9630 | 0.6950 |
insecticides, along with previously reported SsoPox monovariants harboring mutation at residue 263 and their specificity spectrum was determined.

Results and Discussion
The lactonase SsoPox was engineered for higher phosphotriesterase activity using structure-based combinatorial libraries. By comparing structures of enzymes with similar topology, it has been possible to redesign, using modelling tools, the active site cavity of SsoPox to mimic as closely as possible that of BdPTE (Fig. 1; Table S1). This method consisted of two main steps: (i) the identification of mutations corresponding to equivalent positions at the enzyme active sites using structural alignment and (ii) the rational selection of mutations, in a position with no equivalent residue, which mimicked the shape and chemical nature of the target enzyme cavity. A mutation dataset was thus obtained and used to develop a combinatorial library consisting of random combinations of our pre-selected mutations.

Figure 1. Structure-based design approach. (A) Pipeline used for the selection of improved mutants. (B) Structural alignments of SsoPox (red) and BdPTE structures (yellow) guided the mutational design. (C) Active site superposition of BdPTE (green) and SsoPox (cyan) active sites. Residues with structural equivalent (orange sticks) in both structures were used to design mutations of SsoPox’s residues into the BdPTE corresponding residues. Positions with no structural equivalent (red sticks) were designed using modelling tools (purple sticks) to mimic the active site cavity size, shape and chemical properties of the BdPTE crystal structure model (Figure S1). (D) The mutations data base consists of mutations to the BdPTE sequence when there is a structural equivalence (orange), and of mutations designed when there is no structural equivalence (red). The third set of mutations (black) adds more diversity at two selected positions, 258 and 263. (E) Once the library had been validated, primers carrying mutations were used to shuffle them and generate a gene library with random combinations of selected mutations. (F) The library was screened for paraoxonase activity to identify enzymes with improved proficiency.
Structure-based design produced mutants with improved phosphotriesterase activity. The structure-based design considerably reshaped the active site cavity of SsoPox, theoretically bringing it closer to that of BdPTE, both in shape and nature (Figure S1). A total of 14 key positions within the active site were identified, and were mutated to specific residues, or degenerated into several possible amino acids (see Methods). The paraoxonase activity of 184 randomly selected clones was screened and the 14 best were sequenced. Most of these 14 were found to possess the same mutations (e.g. W263F/L/M/A; 73% of cases) and (Figure S2A; Table S3). Of them, the most active variants, \( \alpha sA1 \) (C258L-I261F-W263A), \( \alpha sA6 \) (F46L-C258A-W263M-I280T), \( \alpha sB5 \) (V27A-I76T-Y97W-Y99F-L130P-L226V), \( \alpha sC6 \) (L72I-Y99F-I122L-L228M-F229S-W263L), and \( \alpha sD6 \) (V27A-Y97W-L228M-W263M) were subject to kinetic and structural characterization. It should be noted that \( \alpha sA1 \) was obtained in a previous engineering effort \(^47\), and that four of the five selected variants contained a substitution of the key residue W263. We previously highlighted the role of this residue in substrate binding and modulation of the active site loop 8 conformation, resulting in an increase in activity against promiscuous substrates \(^11\). Variant \( \alpha sB5 \) does not harbor any substitution at position W263. We therefore decided to test the W263 substitution on an \( \alpha sB5 \) background, using saturation mutagenesis strategy.

The five selected variants (\( \alpha sA1, \alpha sA6, \alpha sB5, \alpha sC6 \& \alpha sD6 \)) were characterized against several phosphotriesters, including ethyl-paraoxon (I), ethyl-parathion (II), methyl-paraoxon (III), methyl-parathion (IV) and malathion (V) (Fig. 2). Overall, all variant exhibits improved catalytic efficiencies against all tested substrates, with the exception of \( \alpha sA1 \) with malathion (~2-fold decrease) (Fig. 3A; Table 2). The best improved variant, \( \alpha sD6 \), exhibits a 2,210-fold increase in catalytic efficiency against methyl-parathion (Table 2). The largest improvements were observed for ethyl/methyl-parathion, two bad substrates for wild-type SsoPox. Interestingly, while the \( \text{wt} \) enzyme shows a clear preference for small substituents \(^46\), most selected variants lost this preference, possibly indicating an enlargement of the active site cavity. These improvements were in the range of what was previously obtained but with higher intensive mutation protocols and for only one OP substrate \(^49\). Finally, it was noted that two variants (\( \alpha sA6 \& \alpha sC6 \)) presented a substrate inhibition for some thiono-phosphotriesters.

The five selected variants were further evaluated for their lactonase activity (Table 2). Interestingly, variants \( \alpha sA6 \) and \( \alpha sC6 \) exhibit enhanced lactonase activity against \( \gamma \)- and \( \delta \)-lactones, while \( \alpha sA1, \alpha sB5 \) and \( \alpha sD6 \) show reduced lactonase catalytic efficiencies. This emphasizes the fact that the improvement of the phosphotriesterase activity does not necessarily compromise the cognate, lactonase activity of the enzyme. These mutations therefore dramatically increased a new activity (phosphotriesterase) without the complete loss of the native/original function (lactonase) \(^4\). These mutants are different from those generated on another PLLs, through loop insertion. While the stepwise insertion of residues in loop 7 can significantly increase the ability of PLLs to degrade phosphotriesters, it also drastically decreases their lactonase activity \(^43\). Insertion in loop 7 has been previously described as a key evolutionary event in the transition from lactonase to phosphotriesterase \(^50\).
Structural analysis of improved variants reveals increased mobility of the active site loop 8.

The crystal structures of variants $\alpha_{sA1}$, $\alpha_{sA6}$, $\alpha_{sB5}$, $\alpha_{sC6}$ and $\alpha_{sD6}$ were solved (Table 1). While most structures were solved at high or medium resolutions (1.4–2.55 Å), mutant asD6 could only be solved at low resolution (2.95 Å). Given this resolution, we limited our interpretations and retained this data for the consistency of the study as it exhibits structural features (loop 8 disorder) that are consistent with all the other mutants. Overall, the mutants' structures are similar to that of wt-$SsoPox$. However, the active site cavities are larger for the mutants: most selected mutations replace residues with smaller ones: W263 is mutated into M/L/I, V27 into A, I76 into T, L130 into P, Y99 into F. Only two selected substitutions relate to bulkier side chains: Y97W and L228M. This enlargement is difficult to quantify even with the structure of these mutants because of the extremely mobile nature of loop 8 in the variants. Enlarging the active site was a main objective of the active site redesign of $SsoPox$, to enable the bulkier phosphotriesters to bind within the natural lactonase enzyme. Additionally, the loop 8 conformations differ in mutants, as compared to the wt-enzyme. Because part of loop 8, including position 263, is located at the enzyme dimer interface, altered loop 8 conformations modulate the relative orientation of both monomers. In the case of the mutants characterized in this study, the dimer reorientation yields significant displacement up to 5.2 Å (e.g., $\alpha_{sA1}$, between equivalent carbon $\alpha$ positions), as compared to wt-$SsoPox$ (Figure S5).

Similar reorientations were previously observed upon substrate binding or mutations of W263.11,42

Although the active sites of the improved variant structures superpose well onto the wt-structure, all selected mutants display altered loop 8 conformations. Changes are subtle for some of the variants (e.g. $\alpha_{sA1}$), but are large for others (e.g. $\alpha_{sC6}$) (Fig. 4). Notably, mutant $\alpha_{sA6}$ was crystallized in two different conformations: one in which loop 8 adopts a wt-like conformation, referred to as open conformation (OC) (Figure S6). In the two other mutants, $\alpha_{sD6}$ and $\alpha_{sB5}$, loop 8 could not be modeled due to the lack of electronic density, which was likely to be due to the high level of motion of this enzyme region. Analysis of the normalized thermal motion B-factor supports this hypothesis. It also confirms that loop 8 is highly mobile in all selected mutants, as compared to wt-$SsoPox$ (Fig. 5). The higher mobility of loop 8 may also partly explain the improved ability of the variants to hydrolyze phosphotriesters with large substituents.

Improved mutant $\alpha_{sD6}$ lost the thiono-effect. $SsoPox$ presents a marked preference for oxono-OP substrates as compared to thiono-ones (>100-fold in catalytic efficiency).46 Conversely, PTEs do not exhibit such a drastic preference, paraoxon being a slightly better substrate than parathion for the enzyme.27,51 Interestingly,
| Substrate                     | SsoPox | $k_{cat}$ (s$^{-1}$) | $K_{m}$ (µM) | $V_{max}/K_{m}$ (µmol·s$^{-1}$·µM$^{-1}$) |
|-----------------------------|--------|---------------------|--------------|------------------------------------------|
| Ethyl-paraoxon (I)          | wt*    | 2.16 ± 0.13 × 10$^4$ | 2.43 ± 0.37 × 10$^3$ | 5.12 ± 1.31 × 10$^4$ |
|                            | CSA1   | 2.70 ± 0.23 × 10$^4$ | 8.00 ± 1.55 × 10$^3$ | 3.37 ± 0.71 × 10$^4$ |
|                            | CSA6   | 5.87 ± 0.47         | 1.63 ± 0.63 × 10$^3$ | 3.61 ± 1.43 × 10$^7$ |
|                            | CSA5   | 2.06 ± 0.14 × 10$^4$ | 6.01 ± 0.96 × 10$^3$ | 3.43 ± 1.46 × 10$^5$ |
|                            | CSA6   | 4.27 ± 0.25 × 10$^4$ | 1.50 ± 0.16 × 10$^3$ | 2.86 ± 0.35 × 10$^5$ |
|                            | CSA6   | 3.22 ± 0.18 × 10$^4$ | 1.09 ± 0.12 × 10$^3$ | 2.95 ± 1.55 × 10$^5$ |
|                            | CSA5   | *                   | *             | 5.62 ± 0.11 × 10$^5$ |
|                            | CSA5   | *                   | *             | 8.07 ± 0.28 × 10$^5$ |
|                            | CSA5   | 4.09 ± 0.89 × 10$^4$ | 6.64 ± 1.75 × 10$^3$ | 6.16 ± 5.07 × 10$^4$ |
|                            | W263L* | *                   | *             | 2.37 ± 0.33 × 10$^4$ |
|                            | W263M* | 6.82 ± 0.57         | 9.31 ± 1.63 × 10$^3$ | 7.33 ± 1.42 × 10$^5$ |
| Ethyl-parathion (II)        | wt*    | ND                  | ND           | ND                                       |
|                            | CSA1   | ND                  | ND           | ND                                       |
|                            | CSA6   | 3.20 ± 0.20 × 10$^{-2}$ | 1.34 ± 0.18 × 10$^3$ | 2.50 ± 1.02 × 10$^3$ |
|                            | CSA5   | 2.69 ± 0.15 × 10$^{-1}$ | 2.72 ± 0.49 × 10$^3$ | 9.86 ± 3.14 × 10$^3$ |
|                            | CSA6   | 8.53 ± 0.30 × 10$^{-3}$ | 7.70 ± 1.10 × 10$^3$ | 1.10 ± 0.16 × 10$^3$ |
|                            | CSA6   | 7.35 ± 0.36 × 10$^{-3}$ | 5.34 ± 0.62 × 10$^3$ | 1.38 ± 0.57 × 10$^3$ |
|                            | CSA5   | 5.24 ± 0.23 × 10$^{-2}$ | 2.02 ± 0.31 × 10$^3$ | 2.59 ± 0.74 × 10$^3$ |
|                            | CSA5   | 4.35 ± 0.16 × 10$^{-2}$ | 3.46 ± 0.53 × 10$^3$ | 1.26 ± 0.44 × 10$^4$ |
|                            | CSA5   | 4.74 ± 0.21 × 10$^{-2}$ | 2.61 ± 0.37 × 10$^3$ | 1.82 ± 0.57 × 10$^4$ |
| Methyl-paraoxon (III)       | wt*    | 2.71 ± 0.64         | 2.14 ± 0.68 × 10$^3$ | 1.27 ± 0.70 × 10$^3$ |
|                            | CSA1   | 4.35 ± 0.87 × 10$^3$ | 1.90 ± 0.52 × 10$^3$ | 2.29 ± 0.78 × 10$^3$ |
|                            | CSA6   | 5.89 ± 0.55         | 5.46 ± 1.02 × 10$^3$ | 1.08 ± 0.23 × 10$^3$ |
|                            | CSA5   | *                   | *             | 4.31 ± 0.14 × 10$^4$ |
|                            | CSA6   | 2.36 ± 0.37 × 10$^3$ | 7.59 ± 2.04 × 10$^3$ | 3.11 ± 0.97 × 10$^4$ |
|                            | CSA6   | 4.25 ± 0.52 × 10$^3$ | 2.08 ± 0.34 × 10$^3$ | 2.04 ± 0.42 × 10$^3$ |
| Methyl-parathion (IV)       | wt*    | 1.10 ± 0.02 × 10$^{-3}$ | 1.21 ± 0.10 × 10$^3$ | 9.09 ± 0.90 × 10$^4$ |
|                            | CSA1   | 1.30 ± 0.50 × 10$^{-2}$ | 3.53 ± 0.34 × 10$^3$ | 3.68 ± 1.46 × 10$^6$ |
|                            | CSA6   | 1.55 ± 0.15 × 10$^{-2}$ | 2.54 ± 0.39 × 10$^3$ | 1.520 ± 384 × 10$^3$ |
|                            | CSA5   | 1.50 ± 0.04 × 10$^{-1}$ | 1.58 ± 0.15 × 10$^3$ | 9.49 ± 0.94 × 10$^3$ |
|                            | CSA6   | 3.00 ± 0.10 × 10$^{-3}$ | 1.21 ± 0.15 × 10$^3$ | 2.48 ± 0.32 × 10$^3$ |
|                            | CSA6   | 6.89 ± 0.35         | 3.43 ± 0.44 × 10$^3$ | 2.01 ± 0.28 × 10$^4$ |
| Malathion (V)               | wt*    | 8.90 ± 0.40 × 10$^{-4}$ | 1.60 ± 0.29 × 10$^3$ | 5.56 ± 1.26 × 10$^4$ |
|                            | CSA1   | 7.10 ± 0.40 × 10$^{-4}$ | 2.22 ± 0.35 × 10$^3$ | 3.20 ± 0.54 × 10$^3$ |
|                            | CSA6   | 1.84 ± 0.16 × 10$^{-2}$ | 9.13 ± 1.61 × 10$^3$ | 2.02 ± 1.01 × 10$^3$ |
|                            | CSA6   | 2.47 ± 0.44 × 10$^{-3}$ | 5.20 ± 1.90 × 10$^3$ | 820 ± 343 × 10$^3$ |
|                            | CSA6   | 1.00 ± 0.02 × 10$^{-1}$ | 1.13 ± 0.10 × 10$^3$ | 9.08 ± 2.00 × 10$^3$ |
|                            | CSA5   | 8.92 ± 0.67 × 10$^{-3}$ | 8.61 ± 1.32 × 10$^3$ | 1.04 ± 0.51 × 10$^3$ |
|                            | CSA5   | 1.11 ± 0.08 × 10$^{-2}$ | 9.28 ± 1.32 × 10$^3$ | 1.20 ± 0.60 × 10$^3$ |
|                            | CSA5   | 1.18 ± 0.08 × 10$^{-2}$ | 7.80 ± 1.08 × 10$^3$ | 1.51 ± 0.71 × 10$^3$ |
| Chlorpyrifos (VI)           | wt     | ND                  | ND           | ND                                       |
|                            | CSA6   | *                   | *             | 3.12 ± 0.09 × 10$^3$ |
|                            | CSA5   | *                   | *             | 3.07 ± 0.50 × 10$^3$ |
|                            | CSA5   | *                   | *             | 1.64 ± 3.03 × 10$^3$ |
|                            | CSA5   | *                   | *             | 1.46 ± 3.03 × 10$^3$ |
|                            | CSA5   | *                   | *             | 1.42 ± 3.03 × 10$^3$ |
|                            | W263L  | ND                  | ND           | ND                                       |
|                            | W263M  | ND                  | ND           | ND                                       |
| Continued                  |        |                     |              |                                          |

**Note:** ND indicates not determined.
| Substrate     | SsPox  | K_{cat} (s^{-1}) | K_{m} (µM) | K_{cat}/K_{m} (M^{-1}·s^{-1}) | Enhancement/ wt |
|--------------|--------|-----------------|-------------|-------------------------------|----------------|
| **Diazinon (VII)** |        |                 |             |                               |                |
| wt           | ND     | ND              | ND          | ND                            | ND             |
| cysD6        | 8.93 ± 0.79 | 2.30 ± 0.31 × 10^3 | 3.89 ± 2.56 × 10^3 | ND                            | ND             |
| cysB5        | 1.26 ± 0.06 | 4.10 ± 0.65 × 10^2 | 3.03 ± 0.98 × 10^2 | ND                            | ND             |
| cysB5 W263M  | 3.89 ± 0.38 × 10^{-1} | 3.91 ± 1.04 × 10^3 | 9.92 ± 3.65 × 10^3 | ND                            | ND             |
| cysB5 W263L  | 5.61 ± 0.23 × 10^{-1} | 4.74 ± 0.53 × 10^3 | 1.18 ± 0.44 × 10^3 | ND                            | ND             |
| cysB5 W263I  | 4.01 ± 0.30 × 10^{-4} | 3.24 ± 0.72 × 10^2 | 1.24 ± 0.42 × 10^2 | ND                            | ND             |
| W263L        | ND     | ND              | ND          | ND                            | ND             |
| W263M        | ND     | ND              | ND          | ND                            | ND             |
| W263M        | ND     | ND              | ND          | ND                            | ND             |
| **Fenitrothion (VIII)** |        |                 |             |                               |                |
| wt           | ND     | ND              | ND          | ND                            | ND             |
| cysD6        | 7.94 ± 0.50 × 10^{-1} | 5.28 ± 0.80 × 10^3 | 1.50 ± 0.62 × 10^3 | ND                            | ND             |
| cysB5        | 1.40 ± 0.20 × 10^{-2} | 3.14 ± 1.43 × 10^3 | 9.11 ± 1.40 × 10^3 | ND                            | ND             |
| cysB5 W263M  | 2.22 ± 0.12 × 10^{-2} | 3.31 ± 0.53 × 10^3 | 6.69 ± 2.31 × 10^3 | ND                            | ND             |
| cysB5 W263L  | 2.63 ± 0.13 × 10^{-2} | 6.54 ± 0.75 × 10^2 | 4.01 ± 1.79 × 10^3 | ND                            | ND             |
| cysB5 W263I  | 2.01 ± 0.08 × 10^{-5} | 3.97 ± 0.46 × 10^3 | 5.05 ± 1.81 × 10^3 | ND                            | ND             |
| W263L        | 3.66 ± 0.15 × 10^{-3} | 4.15 ± 0.44 × 10^2 | 8.82 ± 3.32 | ND                            | ND             |
| W263M        | 9.49 ± 0.43 × 10^{-4} | 1.57 ± 0.28 × 10^2 | 6.06 ± 1.55 | ND                            | ND             |
| **Fen sulfoothion (IX)** |        |                 |             |                               |                |
| wt           | ND     | ND              | ND          | ND                            | ND             |
| cysB5        | 4.28 ± 0.39 × 10^{-2} | 9.41 ± 1.72 × 10^3 | 4.55 ± 2.30 × 10^3 | ND                            | ND             |
| cysD6        | 4.06 ± 1.60 × 10^{-1} | 8.60 ± 3.97 × 10^3 | 4.72 ± 4.04 × 10^3 | ND                            | ND             |
| cysB5 W263M  | *      | *               | 1.12 ± 0.46 × 10^4 | ND                            | ND             |
| cysB5 W263L  | 4.94 ± 1.35 × 10^{-2} | 2.57 ± 1.04 × 10^3 | 1.92 ± 1.30 × 10^4 | ND                            | ND             |
| cysB5 W263I  | *      | *               | 6.50 ± 0.07 | ND                            | ND             |
| W263L        | ND     | ND              | ND          | ND                            | ND             |
| W263M        | ND     | ND              | ND          | ND                            | ND             |
| **Coumaphos (X)** |        |                 |             |                               |                |
| wt           | ND     | ND              | ND          | ND                            | ND             |
| cysD6        | *      | *               | 1.64 ± 0.02 × 10^4 | ND                            | ND             |
| cysB5        | *      | *               | 7.82 ± 0.14 × 10^4 | ND                            | ND             |
| cysB5 W263M  | *      | *               | 1.15 ± 0.02 × 10^4 | ND                            | ND             |
| cysB5 W263L  | *      | *               | 1.16 ± 0.05 × 10^4 | ND                            | ND             |
| cysB5 W263I  | *      | *               | 1.11 ± 0.04 × 10^4 | ND                            | ND             |
| W263L        | *      | *               | 6.01 ± 0.18 | ND                            | ND             |
| W263M        | *      | *               | 4.80 ± 0.32 | ND                            | ND             |
| **3-oxo-C10-AHL (f) (XI)** |        |                 |             |                               |                |
| wt*          | *      | *               | 3.16 ± 10^5 | 1                             |                |
| cysA1        | *      | *               | 1.41 ± 10^5 | 0.004                         |                |
| cysA6        | *      | *               | 1.78 ± 10^5 | 0.06                          |                |
| cysB5        | ND     | ND              | ND          | ND                            | ND             |
| cysC6        | *      | *               | 5.84 ± 10^2 | 0.02                          |                |
| cysD6        | ND     | ND              | ND          | ND                            | ND             |
| **Undecanoic-γ-lactone (XII)** |        |                 |             |                               |                |
| wt*          | *      | *               | 2.36 ± 10^5 | 1                             |                |
| cysA1        | *      | *               | 1.63 ± 10^5 | 0.7                           |                |
| cysA6        | *      | *               | 4.40 ± 10^5 | 186                           |                |
| cysB5        | *      | *               | 9.05 ± 10^5 | 0.4                           |                |
| cysC6        | *      | *               | 5.73 ± 10^5 | 243                           |                |
| cysD6        | *      | *               | 1.60 ± 10^5 | 7                             |                |
| **Undecanoic-δ-lactone (XIII)** |        |                 |             |                               |                |
| wt*          | *      | *               | 7.86 ± 10^5 | 1                             |                |
| cysA1        | *      | *               | 2.55 ± 10^5 | 0.03                          |                |
| cysA6        | *      | *               | 9.65 ± 10^5 | 123                           |                |
| cysB5        | *      | *               | 5.33 ± 10^5 | 0.08                          |                |
| cysC6        | *      | *               | 3.60 ± 10^5 | 5                             |                |
| cysD6        | *      | *               | 7.50 ± 10^5 | 0.9                           |                |

Table 2. Kinetic characterization of SsPox variants. *Corresponds to undetermined values because enzyme saturation could not be reached. ND corresponds to undetectable values because substrates were not hydrolyzed or too poorly hydrolyzed to be observable. †Data taken from Hiblot et al.10. ‡Data taken from Hiblot et al.11.
between the thiono moiety and the metal cations (low \(K_M\) value), which would subsequently impair catalysis (low \(k_{cat}\) values)\(^\text{22}\). Interestingly, the improved variants do not exhibit significant difference in \(K_M\) values for thiono-phosphotriesters, but show a dramatic increase in \(k_{cat}\) values, as compared to wild-type enzymes (e.g. \(k_{cat}\) value of 6.89 s\(^{-1}\) and 1.10 \(\times\) 10\(^{-3}\) s\(^{-1}\), as compared to methyl-parathion for the \(\alpha\text{sD6}\) variant and wild-type enzymes, respectively). The two selected variants, namely \(\alpha\text{sB5}\) and \(\alpha\text{sD6}\), which lost the thiono-effect have only two mutations in common: V27A and Y97W. Both residues are located relatively close to the bi-metallic active site, yet do not interact directly with the metals (V27-Fe: 6.7 Å, Y97-Co: 4.3 Å; Fig. 6). Because other PLLs have been shown to exhibit high charge contribution between the β metal and the conserved tyrosine residue\(^{33,34}\), Y97 is a likely candidate for the thiono-effect, and will be examined in future studies.

**Mutations of W263 and \(\alpha\text{sB5}\) are incompatible.** \(\alpha\text{sB5}\) (V27A-I76T-Y97W-Y99F-L130P-L226V) is the only selected mutant that does not contain a substitution of position W263. Because W263 substitutions were previously shown to be key for increasing SsoPox’s phosphotriesterase activity, we used saturation mutagenesis to introduce W263 mutations to the background of \(\alpha\text{sB5}\)\(^\text{22}\). The best selected mutants against paraoxon (Figure S2C) were found to be \(\alpha\text{sB5-W263L/M}\). Surprisingly, none of these mutants demonstrated an increase in phosphotriesterase activity in comparison with \(\alpha\text{sB5}\), but rather a decrease in activity (Table 2). This is intriguing because, taken individually, these mutations have been shown to greatly improve phosphotriesterase activity. For example, with ethyl-paraoxon as a substrate, W263M and \(\alpha\text{sB5}\) produce a catalytic efficiency improvement of 14 and 67-fold, respectively, while the combination \(\alpha\text{sB5-W263M}\) increases activity only 11-fold (Table 2). This example of negative epistasis could be due to the mode of action of these mutations. Structures reveal that \(\alpha\text{sB5}\) mutations have a destabilizing effect on loop 8, as illustrated by the B factor analysis. The same was observed for W263M in a previous study\(^\text{11}\). Combining these two destabilizing sets of mutations may have harmed the active site integrity, as previously described with another enzyme as “conformational active site disorder”\(^\text{46}\), and in particular the necessary alignment and pre-organization of the catalytic residues. The destabilizing effect of these mutations can also be observed on the overall enzyme stability, with \(\alpha\text{sB5-W263M}\) exhibiting \(T_m\) values of 70.4 °C, 85.3 °C and 69.1 °C, respectively, as compared to 106 °C for the wt enzyme (Table S4). Here, the effects of the combined 5 mutations harbored by variant \(\alpha\text{sB5}\) together with the previously identified positive substitutions at residue W263 were not additive underlining that single beneficial mutations do not necessarily induce positive epistatic effects. Synergistic effects of mutations are often complex to predict and most engineering strategies usually lead to an optimization plateau difficult to overcome\(^\text{35}\).

**Improvement of engineered variants over W263 mutation.** In a previous report, we noted that mutation of W263 into all the other 19 residues lead to an increase of the promiscuous paraoxonase activity\(^\text{11}\). Here we note that most of the improved variants (i.e. \(\alpha\text{sA1, \alpha\text{sA6, \alpha\text{sB5, \alpha\text{sC6 & \alpha\text{sD6}}}}\) (i) exhibit higher paraoxonase activity than W263L/M, and (ii) foremost are capable of hydrolyzing phosphotriesters that are not substrates for the wild-type enzyme or W263 mutants, such as ethyl-parathion, chlorpyrifos or fensulfothion (Table 2). The activity spectrum of these engineered variants against the tested phosphotriesters is therefore much wider than the wild-type enzyme and W263 mutants.

**Relation between active site loop disorder and broad enzymatic specificity.** The organophosphorus compound bioremediation potential of several mutants was investigated. In particular, the best variants, \(\alpha\text{sD6}\) and \(\alpha\text{sB5}\), alongside other improved variants \(\alpha\text{sB5-W263L/M, W263L/M and the wt-enzyme, were characterized for their phosphotriesterase activity with ethyl-paraoxon (I), ethyl-parathion (II), malathion (V), chlorpyrifos (VI), diazinon (VII), fenithrothion (VIII), fensulfothion (IX) and coumaphos (X) (Fig. 2). Interestingly, we found that most mutants were able to hydrolyze fensulfothion, previously reported as an inhibitor of the wild-type enzyme\(^\text{46}\). Fensulfothion was indeed previously shown to bind head-to-tail into the wild-type enzyme active site\(^\text{46}\), a non-productive binding mode. Changes in the active site loop 8 conformational ensemble of engineered mutants might have allowed for the productive binding of fensulfothion.

All mutants selected and used in this study are destabilized as compared to the wt-enzyme (Fig. 7; Table S4). Structures reveal that these mutations, located on loop 8, contribute to increasing the mobility of the loop. Interestingly, the ability of the tested mutants to hydrolyze a wide range of phosphotriesters, including compounds that were inhibitors for the wt-enzyme, correlates with a lower \(T_m\) (Fig. 7). This correlation suggest that the active site loop 8 degree of disorder may modulate the enzyme’s ability to bind and hydrolyze a variety of phosphotriesters, a wider conformational ensemble of loop 8 being correlated with a broader enzyme specificity. This observation is consistent with previous studies highlighting the importance of the destabilization of active site loops to evolve new activities and new substrate specificity\(^\text{26,28}\). Such flexible active site loops involved in enzymatic specificity supports the notion of fold polarity: a portion of the active site (e.g. the loop) is weakly connected to the enzyme scaffold and thereby makes it possible for new functions to evolve with few changes\(^\text{27}\).

**Mutant \(\alpha\text{sD6}\) is an active, broad spectrum phosphotriester biodecontaminant.** Mutant \(\alpha\text{sD6}\) was further investigated for bioremediation considerations. Organophosphate-based pesticides are usually spread in concentrations in the millimolar range leading to micromolar-ranged contaminations. We thus investigated the potential of \(\alpha\text{sD6}\) for decontaminating pesticide solutions at 250\(\mu\)M to simulate a contamination of ground-water or runoff waters. We investigated two \([E]/[S]\) ratios, \(10^{-2}\) and \(10^{-3}\) respectively, for decontaminating OP solutions and determined the time required to hydrolyze 95% of pesticide preparations (Fig. 3B; Figure S4). When considering the \([E]/[S]\) ratio of \(10^{-3}\), 95% degradation was achieved for four substrates (ethyl-paraoxon, diazinon, fenithrothion and coumaphos) within 10 minutes. Two substrates were decontaminated within an hour (ethyl-parathion and chlorpyrifos) and fensulfothion was degraded in three hours.
When increasing enzyme concentration 10-fold ([E]/[S] ratio of $10^{-2}$), five substrates (ethyl-paraoxon, ethyl-parathion, diazinon, fenitrothion and coumaphos) were decontaminated within two minutes, while fensulfothion needed ~20 minutes and the two other tested (chlorpyrifos and malathion) required 40 minutes. Given

**Figure 4.** Loop 8 conformations in improved mutants. Active site loop 8 region of mutant structures superimposed with the wt-SsoPox structure. The active site location is indicated by the presence of the bimetallic catalytic center shown as spheres. The wt-SsoPox structure loop 8 conformation is shown as dark green cartoon. (A) ωA1’s loop 8 is shown in orange cartoon, (B) ωD6’s loop 8 is shown in green cartoon, and is not entirely visible in the electronic density maps, (C) ωC6’s loop 8 is shown in blue cartoon, (D) ωB5’s loop 8 is shown in yellow cartoon, and is not entirely visible in the electronic density maps, (E) ωA6-CC’s loop 8 is shown in magenta cartoon, (F) ωA6-OC’s loop 8 is shown in cyan cartoon.
both its catalytic proficiency and high thermal stability ($T_m = 82.5 \, ^\circ C$), $\alpha$sD6 is a promising candidate for organophosphorus compound bioremediation and, in particular, the decontamination of water runoffs, soils, food products and materials. Moreover, SsoPox variants were previously shown to be compatible with immobilization steps including alginate beads and polyurethane-based coatings$^{48,58}$, and could be of prime interest for the development of filtration devices for water treatment purposes.

**Methods**

**Structure-based identification of mutations.** Sharing the same ($\alpha/\beta$)$_8$ barrel topology, SsoPox and BdPTE structures (Pdb ID 2vc5 and 1dpm, respectively) were superimposed (Fig. 1) using PyMol$^{59}$, making it possible to identify structurally equivalent residues at their respective active sites. In an effort to reshape the SsoPox active site, side chains that were well superimposed between the two enzymes were mutated using Coot into the residue present in BdPTE$^{60}$, with the exception of V27 which was mutated in Ala (and not Gly) to avoid increased entropy (Fig. 1; Table S1). However, due to the major differences in loop 8 and 7 between PLLs and PTEs, numerous residues were not superimposable. These active site residues (T99, L228, F229 and W263) were therefore mutated in an effort to mimic the BdPTE active site cavity in terms of shape and chemical nature, as
illustrated by the chimeric reconstruction of SsoPox carrying all these mutations (Figure S1). Others mutations were also implemented in the dataset, e.g. C258A and C258L and different substitutions of the key position W263 (F/L/M/A) that have been shown to improve the phosphodiesterase activity 11.

Synthesis of the combinatorial library. The SsoPox coding gene was amplified from the previously described pET22b-SsoPox plasmid 46. For each of the 14 mutations, a mutagenesis primer of 30–33 bp (~10–15 bp from each mutation side) was synthesized (Table S2). For close mutations, primers can share several mutations and different primers were synthesized and mixed to keep an equivalent statistical probability for each of the 14 mutations. Typically, 2 pmol of primer mixture and 100 ng of DNaseI (TaKaRa)-generated fragments of the SsoPox gene were assembled as previously described 17, followed by nested PCR with external cloning primers (SsoPox-lib-pET-5’/3’) (Table S2). The PCR product was then cloned into a customized version of the pET-32b(-ΔTrx) plasmid and then electroporated into E. coli cells (Lucigen, USA). After agar-plate growth, plasmid extraction was performed to create the plasmid bank. Variant genes were PCR amplified using T7-prom and

---

**Figure 6.** Localization of mutations harbored by SsoPox monovariants, αsA1, αsA6, αsB5, αsC6 and αsD6. Mutations are highlighted in red spheres using the SsoPox wild-type (PDB 3UF9) as a template.

**Figure 7.** Overview of SsoPox wild-type and variants properties. Catalytic efficiencies towards organophosphate-based pesticides are presented using a color code ranging from white to dark blue. Melting temperatures are presented using a color code ranging from red to green.
pET-RP primers (Table S2) and sequenced. The combinatorial library shows an average of 5.3 ± 3.3 library mutations by sequencing 10 randomly picked colonies, and 0.43 ± 0.53 random mutations per gene.

**Screening of the library.** The plasmid library was used to transform the *Escherichia coli* strain BL21(DE3)-pGro7/GroEL (TaKaRa) to obtain colonies expressing a library of SsoPox variants. Randomly picked clones (184), representing a coverage of 3.8% of the library, were grown on a 96-well plate in 500 µL of ZYP medium as previously described 15. Production of proteins and chaperones was induced after five hours of culture at 37 °C by reducing the temperature to 25 °C, adding CoCl$_2$ (0.2 mM) and adding arabinose (0.2%, w/v). After overnight growth, cell lysate was used to perform activity screening with 100 µM of paraoxon substrate (Figure S2B) after partial purification of the protein with a heating step of 15 minutes incubation at 70 °C 35,49. The screening was performed in 50 mM HEPES pH 8, 150 mM NaCl, 0.2 mM CoCl$_2$. Kinetics of paraoxon/methyl-parathion hydrolysis were monitored by following absorbance at 405 nm for 10 minutes using a microplate reader (Synergy HT, BioTek, USA) and the Gen5.1 software.

**Saturation library.** Saturation mutagenesis directed on residue 263 of the αsB5 variant encoding gene, was performed using NNS degenerated primers (W263NNS direct: 5′-TGCACCATTGATNNSGGCACCGGAAGACCG -3′ and W263NNS reverse: 5′-CGGTTTTGCCTGCCSNNATCAATTGTTGA-3′) and pET32b-ΔTrx carrying αsB5 coding gene as template. PCR amplification was performed with 2.5 U of PfuTurbo DNA polymerase (Agilent) according to the manufacturer’s recommendations [95 °C, 5 minutes; 20x (95 °C, 30 seconds; 55 °C, one minute; 68 °C, 15 minutes); 68 °C, 25 minutes]. DNA was digested with DpnI to remove the methylated parental template. *E. coli* BL21(DE3)-pGro7/GroEL (TaKaRa) competent cells were transformed with the plasmid pool and plated on LB-agar supplemented with 100 µg.mL$^{-1}$ ampicillin and 34 µg.mL$^{-1}$ chloramphenicol. Over a theoretical diversity of 20 sequences, 181 variants were collected in a microplate containing LB (100 µg.mL$^{-1}$ ampicillin and 34 µg.mL$^{-1}$ chloramphenicol) for characterization. This oversampling by a factor of nearly 10-fold ensure a >99% probability to get the 20 possible substitutions.

Screening was performed as described above (Figure S2C). Clones were produced in liquid ZYP medium and their activity was screened with 100 µM of paraoxon substrate. The plasmids corresponding to the most interesting variants were extracted and the SsoPox variant encoding genes were sequenced.

**Production-purification of SsoPox wild-type and variants.** The genes coding for the SsoPox wild-type and its variant were cloned in a pET32b-ΔTrx plasmid. Productions were performed using the *E. coli* BL21(DE3)-pGro7/GroEL (TaKaRa) chaperone expressing strain. Starter cultures were produced in an auto-inducible ZYP medium (supplemented with 100 µg.mL$^{-1}$ ampicillin and 34 µg.mL$^{-1}$ chloramphenicol). When OD$_{600nm}$ reached a value of 0.8–1, CoCl$_2$ was added (final concentration 0.2 mM) as well as L-arabinose (ε$_{412}$ nm, (5 minutes). Production-purification of SsoPox variants. Randomly picked clones (184), representing a coverage of 3.8% of the library, were grown on a 96-well plate in 500 µL of ZYP medium as previously described 11. Production of proteins and chaperones was induced after five hours of cultivation by sequencing 10 randomly picked colonies, and 0.43 ± 0.53 random mutations per gene.

**Kinetic assays.** **Generalities.** Catalytic parameters were evaluated in triplicate at 25 °C, and recorded using a microplate reader (Synergy HT, BioTek, USA) and the Gen5.1 software, in a 6.2 mm path length cell for 200 µL reaction in 96-well plate, as previously explained 30. Catalytic parameters were obtained by fitting the data to the Michaelis-Menten (MM) equation using Graph-Pad Prism 6 software. When $V_{max}$ could not be reached in the experiments, catalytic efficiency was obtained by fitting the linear part of MM plot to a linear regression using Graph-Pad Prism 6 software. For some SsoPox variants, the MM plot was fitted to the substrate inhibition equation using Graph-Pad Prism 6 software enabling us to determine a $K_s$ for several substrates. Consequently, the calculated catalytic efficiencies in these conditions are true only at low substrate concentrations. In some other cases, saturation could not be reached, therefore $k_{cat}/K_M$ values were determined using linear regression. For Coumaphos, data were fitted to one-phase decay non-linear regression.

**Phosphotriesterase activity characterization.** The kinetic assays were carried out in activity buffer. The conditions used for pesticides were as follows: ethyl-paraoxon (I), ethyl-parathion (II), methyl-paraoxon (III) and methyl-parathion (IV) hydrolysis was recorded at 405 nm ($ε = 17000$ M$^{-1}$.cm$^{-1}$). The concentration interval was between 0.05 and 2 mM from 100 mM stock solution in ethanol 46. Malathion (V) hydrolysis was monitored at 412 nm, ($ε = 13400$ M$^{-1}$.cm$^{-1}$) 46. The concentration interval was between 0.05 and 2 mM from 100 mM stock solution in DMSO. DTNB was added to the activity buffer. Chlorpyrifos (VI) hydrolysis was recorded at 310 nm ($ε = 5562$ M$^{-1}$.cm$^{-1}$) 35. The concentration interval was between 0.05 and 2 mM from 100 mM stock solution in 1-propanol. Diazinon (VII) hydrolysis was recorded at 228 nm ($ε = 3300$ M$^{-1}$.cm$^{-1}$) 27. The concentration interval was between 0.05 and 2 mM from 200 mM stock solution in ethanol. Fenitrothion (VIII) hydrolysis was recorded at 358 nm ($ε = 18700$ M$^{-1}$.cm$^{-1}$) 35. The concentration interval was between 0.05 and 2 mM from 200 mM stock...
solution in ethanol. Fensulfothion (IX) hydrolysis was recorded at 284 nm (ε = 8000 M⁻¹·cm⁻¹)²⁷. The concentration interval was between 0.05 and 2 mM from 200 mM stock solution in methanol. Coumaphos (X) hydrolysis was monitored by fluorescence of released chlorferon (excitation 360/40 and emission 460/40)³⁵. A linear correlation between fluorescence and chlorferon was found (Figure S3). Measurements were taken at 5 µM from a 200 mM stock solution in DMSO. We assumed that $K_{cat}$/$[S]$, thus enabling us to estimate $k_{cat}$/$K_m$.

**Lactonase activity characterization.** Lactonase kinetics were performed using a previously described protocol³⁰. The time course hydrolysis of lactones were performed in lac buffer (2.5 mM Bicine pH 8.3, 150 mM NaCl, 0.2 mM CoCl₂, 0.25 mM Cresol purple and 0.5% DMSO) over a concentration range 0–2 mM for 3-oxo-C10 AHLs (XI) or 0–5 mM for undecan-10-0-lactones (XII, XIII). Cresol purple (pKₐ 8.3 at 25°C) is a pH indicator used to follow lactone ring hydrolysis by acidification of the medium. Molar coefficient extinction at 577 nm was evaluated recording absorbance of the buffer over an acidic range of concentration 0–0.35 mM.

**Bioremediation of pesticide solutions at 250 µM.** For all OP substrates but malathion, experiments were performed in triplicate at 25°C using a microplate reader (Synergy HT, BioTek, USA). Wavelengths were chosen as described in the kinetic assays section. Degradation of malathion was followed by GC/MS in triplicate. OP concentration was fixed at 250 µM. All the substrates were soluble at this concentration. The best variants of SsoPox for each substrate were used, namely αD6 for all the OPs. Two enzyme-to-substrate ratios [E]/[S] were used, 10⁻² and 10⁻³, corresponding to enzyme concentrations of 90 µg.ml⁻¹ and 9 µg.ml⁻¹ respectively. The reactions were monitored until the plateau was reached. Experimental measures were obtained using Gen5.1 software, and then analyzed with GraphPad Prism 6 software. Curves were then fitted using one-Phase Decay non-linear regression with the equation (1):

$$Y = (Y_0 - \text{Plateau}) \times e^{(-kt)} + \text{Plateau}$$ (1)

where $Y_0 = 0$% and Plateau = 100%. The rate constant $k$ was determined and the time required to observe a 95% decontamination was calculated accordingly. The curves and results of the fits are shown in Figure S4.

Degradation at 95% was confirmed using a final point by GC/MS for all pesticides with a 10⁻³ enzyme-to-substrate ratio. 100 µL of activity buffer solution was first extracted with 100 µL chloroform. Organic extracts were analyzed by using a Clarus 500 gas chromatograph equipped with a SQ8S MS detector (Perkin Elmer, Courtaboeuf, France). 1 µL of organic extract was volatilized at 220°C (split 15 mL.min⁻¹) in a deactivated FocusLiner with quartz wool (SGE, Ringwood, Australia) and compounds separated on an Elite-5MS column (30 m, 0.25 mm i.d., 0.25 mm film thickness) for 12 minutes using a temperature gradient (80–280°C at 30°C.min⁻¹, five minutes' hold). Helium flowing at 2 mL.min⁻¹ was used as the carrier gas. The MS inlet line was set at 280°C and the electron ionization source at 280°C and 70 eV. Full scan monitoring was performed from 40 to 400 m/z in order to identify chemicals by spectral database search using MS Search 2.0 operated with the Standard Reference Database 1A (National Institute of Standards and Technology, Gaithersburg, MD, USA). m/z is the mass-to-charge ratio of the base peak fragment detected for each molecule. In the case of weak pesticide signals, extracted ion chromatograms were generated with base peak ions to confirm the presence of chemicals (Paraoxon (I) and Parathion ethyl (II) m/z 109; Malathion (V) and Fenitrothion (VIII) m/z 125; Diazinon (VII) m/z 137; Coumaphos (X) m/z 97; Fensulfothion (IX) m/z 293; and Chlorpyrifos (VI) m/z 197). Selected Ion Recording using base peaks ions was applied in order to specifically monitor pesticides and collect peak areas for kinetics. All samples were analyzed over short periods of time to avoid signal drift. All data were processed using Turbomass 6.1 (Perkin Elmer).

**Crystallization.** Crystallization assays were performed as previously described³²,⁴⁶. Crystallization was performed using the hanging drop vapor diffusion method in 96-well plates (Greiner Microplate, 96 well, PS, F-bottom) on ViewDrop II seals (TPP Labtech). Equal volumes (0.5 µL) of protein and reservoir solutions were mixed, and the resulting drops were equilibrated against a 150 µL reservoir solution containing 20–30% (w/v) PEG 8000 and 50 mM Tris-HCl buffer (pH 8). Crystals appeared after few days at 4°C.

**Data collection and structure refinement.** Crystals were first transferred to a cryoprotectant solution consisting of the reservoir solution and 20% (v/v) glycerol. Crystals were then flash-cooled in liquid nitrogen. X-ray diffraction data were collected at 100 K using synchrotron radiation at the ID23-1 beam line (ESRF, Grenoble, France) and using an ADSC Q315r detector. X-ray diffraction data were integrated and scaled with the XDS package (Table 1)⁴⁹. The phases were obtained using the native structure of SsoPox (PDB code 2vc5) as a starting model, performing a molecular replacement with MOLREP or PHASER²⁸,³⁵. The models were built with Coot and refined using REFMAC⁶⁴. We note that three structures presented in this work exhibit one disordered monomer (and low corresponding electron density): αS85 (monomer D, total of 4 monomers), αS66 (monomer C, out of a total of 4 monomers) and αS6 (monomer C, total of 4 monomers). Structure illustrations were performed using PyMOL.⁴⁸

**Relative B-factor analysis.** The occupancies of all residues in all tested structures were set to 1 for this analysis. For residues with alternate conformations, the sums of occupancies were set to 1. Structures were re-refined with REFMAC⁶⁴. The relative B-factor values were obtained by normalizing the B-factor values of each residue by the average B-factor of the whole structure as previously described¹¹,⁵⁴,⁵⁷.

**References**

1. Wolfenden, R. Benchmark Reaction Rates, the Stability of Biological Molecules in Water, and the Evolution of Catalytic Power in Enzymes. Annu. Rev. Biochem. 80, 645–667 (2011).
2. Singh, R. K., Tiwari, M. K., Singh, R. & Lee, J.-K. From Protein Engineering to Immobilization: Promising Strategies for the Upgradation of Industrial Enzymes. Int. J. Mol. Sci. 14, 1232–1277 (2013).
3. Bar-Even, A. et al. The Moderately Efficient Enzyme: Evolutionary and Physicochemical Trends Shaping Enzyme Parameters. Biochemistry (Mosc.) 50, 4402–4410 (2011).
4. Tokuriki, N. et al. Diminishing returns and tradeoffs constrain the laboratory optimization of an enzyme. Nat. Commun. 3, 1257 (2012).
5. Burton, S. G., Cowan, D. A. & Woodley, J. M. The search for the ideal biocatalyst. Nat. Biotechnol. 20, 37–45 (2002).
6. Gupta, R. D. & Tawfik, D. S. Directed enzyme evolution via small and effective neutral drift libraries. Nat. Methods 5, 939–942 (2008).
7. Bommarius, A. S. Biocatalysis: A Status Report. Annu. Rev. Chem. Biomol. Eng. 6, 319–345 (2015).
8. Currin, A., Swainston, N., Day, P. J. & Kelly, D. B. Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently. Chem Soc Rev 44, 1172–1239 (2015).
9. Reetz, M. T. Directed Evolution of Selective Enzymes: Catalysts for Organic Chemistry and Biotechnology. (Wiley-VCH Verlag GmbH & Co. KGaA, 2016), https://doi.org/10.1002/9783527655465.
10. Directed Enzyme Evolution: Advances and Applications. (Springer International Publishing, 2017), https://doi.org/10.1007/978-3-319-50413-1.
11. Hibbott, J., Gothard, G., Elias, M. & Chabrierie, E. Differential Active Site Loop Conformations Mediate Promiscuous Activities in the Lactonase SsoPos. PLoS ONE 8, e75372 (2013).
12. Reetz, M. T. Laboratory Evolution of Stereoselective Enzymes: A Prolific Source of Catalysts for Asymmetric Reactions. Angew. Chem. Int. Ed. 50, 138–174 (2011).
13. Daudé, D., Topham, C. M., Renaud-Siméon, M. & André, J. Probing impact of active site residue mutations on stability and activity of Neisseria polysaccharea amylase. Protein Sci. 22, 1754–1768 (2013).
14. Alcolombri, U., Elias, M. & Tawfik, D. S. Directed Evolution of Sulfotransferases and Paraoxonases by Ancestral Libraries. J. Mol. Biol. 411, 837–853 (2011).
15. Gonzalez, D. et al. Ancestral mutations as a tool for solubilizing proteins: The case of a hydropathic phosphate-binding protein. FEBS Open Bio 4, 121–127 (2014).
16. Hawwa, R., Larsen, S. D., Ratia, K. & Mesecar, A. D. Structure-Based and Random Mutagenesis Approaches Increase the Organophosphate-Decayng Activity of a Phosphotriesterase Homologue from Deinococcus radiodurans. J. Mol. Biol. 393, 36–57 (2009).
17. Herman, A. & Tawfik, D. S. Incorporating Synthetic Oligonucleotides via Gene Reassembly (ISOR): a versatile tool for generating targeted libraries. Protein Eng. Des. Sel. 20, 219–226 (2007).
18. Rochu, D., Chabrierie, E. & Masson, P. Human paraoxonase: A promising approach for pre-treatment and therapy of organophosphorous poisoning. Toxicology 233, 47–59 (2007).
19. Krieger, R. Handbook of Pesticide Toxicology, Two-Volume Set: Principles and Agents. (Academic Press, 2001).
20. Gupta, R. C. Handbook of Toxicology of Chemical Warfare Agents. (Academic Press, 2009).
21. Sapozhnikova, Y. et al. Evaluation of pesticides and metals in fish from the Dniester River, Moldova. Chemosphere 60, 196–205 (2005).
22. Sapozhnikova, Y., Bawardi, O. & Schlenk, D. Pesticides and PCBs in sediments and fish from the Salton Sea, California, USA. Chemosphere 55, 797–809 (2004).
23. Lejeune, K. E., Wild, J. R. & Russell, A. J. Nerve agents degraded by enzymatic foams. J. Biol. Chem. 264, 19659–19665 (1999).
24. Lejeune, K. E., Wild, J. R. & Russell, A. J. Nerve agents degraded by enzymatic foams. Nature 395, 27–28 (1998).
25. Jacquet, P. et al. Current and emerging strategies for organophosphate deconamination: special focus on hyperstable enzymes. Environ. Sci. Pollut. Res. 1–19 https://doi.org/10.1007/s11356-016-6143-1 (2016).
26. Porzio, E., Merone, L., Mandrich, L., Rossi, M. & Manco, G. A new phosphotriesterase from Sulfolobus acidocaldarius and its comparison with the homologue from Sulfolobus solfataricus. Biochimie 89, 625–636 (2007).
27. Dumas, D. P., Caldwell, S. R., Wild, J. R. & Raushel, F. M. Purification and properties of the phosphotriesterase from Pseudomonas diminuta. J. Biol. Chem. 264, 19659–19665 (1999).
28. Seibert, C. M. & Raushel, F. M. Structural and Catalytic Diversity within the Amidohydrolase Superfamily†. Biochemistry (Mosc.) 44, 6383–6391 (2005).
29. Roodvelt, C. & Tawfik, D. S. Shared Promiscuous Activities and Evolutionary Features in Various Members of the Amidohydrolase Superfamily. Biochemistry (Mosc.) 44, 12728–12736 (2005).
30. Hibbott, J., Gothard, G., Chabrierie, E. & Elias, M. Structural and Enzymatic characterization of the lactonase SisLac from Sulfolobus islandicus. PLoS ONE 7, e47028 (2012).
31. Porzio, E., Merone, L., Mandrich, L., Rossi, M. & Manco, G. A new phosphotriesterase from Sulfolobus acidocaldarius and its comparison with the homologue from Sulfolobus solfataricus. Biochimie 89, 625–636 (2007).
32. Merone, L., Mandrich, L., Rossi, M. & Manco, G. A thermostable phosphotriesterase from the archaean Sulfolobus solfataricus: cloning, overexpression and properties. Extremophiles 9, 297–305 (2005).
33. Hawwa, R., Aikens, J., Turner, R. J., Santarsiero, B. D. & Mesecar, A. D. Structural basis for thermostability revealed through the identification and characterization of a highly thermostable phosphotriesterase-like lactonase from Geobacillus stearothermophilus. Arch. Biochem. Biophys. 488, 109–120 (2009).
34. Xiang, D. F. et al. Functional Identification of Incorrectly Annotated Prolidases from the Amidohydrolase Superfamily of Enzymes. Biochemistry (Mosc.) 48, 3730–3742 (2009).
35. Chow, J. Y. et al. Directed Evolution of a Thermotolerant Quorum-quenching Lactonase from the Amidohydrolase Superfamily. J. Biol. Chem. 285, 40911–40920 (2010).
36. Hiblott, J., Gothard, G., Champion, C., Chabrierie, E. & Elias, M. Crystallization and preliminary X-ray diffraction analysis of the lactonase VmoLac from Vulcanisaeta moutnovskia. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 69, 1235–1238 (2013).
37. Hiblott, J., Badrenga, J., Champion, C., Chabrierie, E. & Elias, M. Crystal structure of VmoLac, a tentative quorum quenching lactonase from the extremophile crenarchaeon Vulcanisaeta moutnovskia. Biochem. J. 437, 8372 (2015).
38. Badrenga, J. et al. SacPox from the thermoacidophilic crenarchaeon Sulfolobus acidocaldarius is a proficient lactonase. BMC Res. Notes 7, 333 (2014).
39. Badrenga, J. et al. Biotechnological applications of quorum quenching enzymes. Chem. Biol. Interact. https://doi.org/10.1016/j.chembioint.2016.05.028 (2016).
40. Rémy, B., Plener, L., Elias, M., Daudé, D. & Chabrierie, E. Des enzymes pour bloquer la communication bactérienne, une alternative aux antibiotiques. Ann. Pharm. Fr. https://doi.org/10.1016/j.annfar.2016.06.005 (2016).
41. Vieille, C. & Zeikus, G. J. Hyperthermophilic Enzymes: Sources, Uses, and Molecular Mechanisms for Thermostability. Microbiol. Mol. Biol. Rev. 65, 1–43 (2001).
42. Elias, M. et al. Structural Basis for Natural Lactonase and Promiscuous Phosphotriesterase Activities. J. Mol. Biol. 379, 1017–1028 (2008).
43. Hoque, M. A. et al. Stepwise Loop Insertion Strategy for Active Site Remodeling to Generate Novel Enzyme Functions. ACS Chem. Biol. https://doi.org/10.1021/acschembio.7b00018 (2017).
44. Meier, M. M. et al. Molecular Engineering of Organophosphate Hydrolysis Activity from a Weak Promiscuous Lactonase Template. J. Am. Chem. Soc. 135, 11670–11677 (2013).
45. Elias, M. et al. Crystallization and preliminary X-ray diffraction analysis of the hyperthermophilic Sulfolobus solfataricus phosphotriesterase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 63, 553–555 (2007).
46. Hiblot, J., Gotthard, G., Chabriere, E. & Elias, M. Characterisation of the organophosphate hydrolyse catalytic activity of SsoPox. Sci. Rep. 2 (2012).
47. Del Guidice, I. et al. An efficient thermostable organophosphate hydrolyse and its application in pesticide decontamination. Biotechnol. Bioeng. 113, 724–734 (2016).
48. Rémy, B. et al. Harnessing hyperthermophilic lactonase from Sulfolobus solfataricus for biotechnological applications. Sci. Rep. 6 (2016).
49. Vecchio, P. D. et al. Structural determinants of the high thermal stability of SsoPox from the hyperthermophilic archaeon Sulfolobus solfataricus. Extremophiles 13, 461–470 (2009).
50. Afrifjørn, L., Jackson, C. J. & Tawfik, D. S. Reconstructing a Missing Link in the Evolution of a Recently Diverged Phosphotriesterase by Active-Site Loop Remodeling. Biochemistry (Moscow) 51, 6047–6055 (2012).
51. Jackson, C. J. et al. Anomalous scattering analysis of Agrobacterium radiobacter phosphotriesterase: the prominent role of iron in the heterobinuclear active site. Biochem. J. 397, 501 (2006).
52. Tawfik, D. S. Accuracy-rate tradeoffs: how do enzymes meet demands of selectivity and catalytic efficiency? Curr. Opin. Chem. Biol. 21, 73–80 (2014).
53. Xiang, D. F. et al. Functional Annotation and Three-Dimensional Structure of Dr0930 from Deinococcus radiodurans: A Close Relative of Phosphotriesterase in the Amidohydrolase Superfamily. Biochemistry (Moscow) 48, 2237–2247 (2009).
54. Dellus-Gur, E. et al. Negative Epistasis and Evolvability in TEM-1 β-Lactamase—The Thin Line between an Enzyme's Conformational Freedom and Disorder. J. Mol. Biol. 427, 2396–2409 (2015).
55. Reetz, M. T. The Importance of Additive and Non-Additive Mutational Effects in Protein Engineering. Angew. Chem. Int. Ed. 52, 2658–2666 (2013).
56. Campbell, E. et al. The role of protein dynamics in the evolution of new enzyme function. Nat. Chem. Biol. 12, 944–950 (2016).
57. Dellus-Gur, E., Toth-Petroczy, A., Elias, M. & Tawfik, D. S. What Makes a Protein Fold Amenable to Functional Innovation? Fold Polarity and Stability Trade-offs. J. Mol. Biol. 425, 2609–2621 (2013).
58. Guendouze, A. et al. Effect of quorum quenching lactonase in clinical isolates of Pseudomonas aeruginosa and comparison with quorum sensing inhibitors. Front. Microbiol. 8 (2017).
59. DeLano, W. L. The PyMOL molecular graphics system (2002).
60. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
61. Kabsh, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26, 795–800 (1993).
62. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
63. Vagin, A. & Teplyakov, A. An approach to multi-copy search in molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 56, 1622–1624 (2000).
64. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255 (1997).

Acknowledgements
This work was granted by DGA, France (REI. 2009 34 0045). G.G. and P.J. are PhD students granted by DGA. Financial support was also obtained from the MnDrive Initiative (M.E.) to support this work. This work was supported by “Investissements d’avenir” program (Méditerranée Infection 10-IAHU-03) of the French Agence Nationale de la Recherche (ANR).

Author Contributions
P.J., J.H., D.D., C.B., M.E. performed the experiments, P.J., J.H., D.D., C.B., N.A., G.G. analyzed the data, P.J., J.H., D.D., C.B., M.E. wrote the manuscript and prepared the figures, E.C., D.D. and M.E. designed the experiments.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-16841-0.

Competing Interests: M.E. and E.C. have a patent WO2014167140 A1 licensed to Gene&GreenTK. D.D. and E.C. report personal fees from Gene&GreenTK during the conduct of the study.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017